Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 24th 2019

Podcast: This Week in Managed Care—CAR T Therapy Coverage and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 22nd 2019

PET Scans Could Identify Patients With Breast Cancer Who May Be Able to Avoid Chemotherapy

Laura Joszt, MA

Researchers have used positron emission tomography scans to identify which patients with a type of human epidermal growth factor receptor 2–positive breast cancer might benefit most from targeted agents alone and can be spared chemotherapy.

February 20th 2019

Pursuing Eradication of Cervical Cancer Through Preventive Interventions

Wallace Stephens

The majority of countries could see an end to cervical cancer as a public health problem by 2060, according to a new study in The Lancet Oncology.

February 19th 2019

Breast Surgeons Seek Genetic Testing for All Patients With Breast Cancer

Mary Caffrey

The update follows a study published in November that found almost no difference in the frequency of mutations between patients with breast cancer who met National Comprehensive Cancer Network guidelines and those who didn't.

February 19th 2019

Humanistic and Economic Burden of Hepatocellular Carcinoma: Systematic Literature Review

Christine G. Kohn, PharmD Prianka Singh, PharmD, MPH Beata Korytowsky, MA Jonathan T. Caranfa, PharmD Jeffrey D. Miller, MS Bruce E. Sill, PharmD, MS Alexander C. Marshall, PharmD, MPH Neehar D. Parikh, MD, MS

Worldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the humanistic and economic burden of HCC.

February 17th 2019

Podcast: This Week in Managed Care—Contraceptive Demand and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 16th 2019

Dr Thomas Martin Outlines How MRD Testing Is Being Used

Currently, minimal residual disease testing is being used for prognostication not for treatment decisions, explained Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center.

February 15th 2019

AJMCtv® Interviews, February 2019

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

February 15th 2019

This Week in Managed Care: February 15, 2019

This week, the top managed care news included increased demand for long-acting contraception since President Trump took office; a payer decision on an insulin pump alarmed diabetes advocates; and despite being involved in cancer treatment decisions, many primary care providers don't feel prepared to do so.

$Patients With Relapsed/Refractory MM More Likely to Have Sustained MRD on Daratumumab$

February 15th 2019

Patients With Relapsed/Refractory MM More Likely to Have Sustained MRD on Daratumumab

Laura Joszt, MA

Minimal residual disease (MRD) is a strong prognosticator of cancer outcomes, and recent research found that patients with relapsed/refractory multiple myeloma (MM) are more likely to achieve MRD on daratumumab than on a standard of care alone.

February 14th 2019

EBO February 2019 Medical World News: Regulatory Updates

Kelly Davio Jaime Rosenberg Laura Joszt, MA Samantha DiGrande

February 14th 2019

Medical World News: Clinical Updates

Kelly Davio Jaime Rosenberg Samantha DiGrande Laura Joszt, MA

February 14th 2019

Moving Toward the "Tipping Point" for Transformation in Cancer Care

Mary Caffrey

Andrew Pecora, MD, FACP, CPE, recently visited Evidence-Based OncologyTM to discuss the progress of COTA’s, a company created in 2011 to develop technology that Pecora said is poised to transform cancer care delivery by helping oncologists and other specialists make decisions that will yield the best outcomes in the most cost-effective way, all at the point of care.

February 14th 2019

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

Mary Caffrey

Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.

February 13th 2019

What We're Reading: Pediatric Mental Health Care; Brain Cancer Immunotherapy; Preventing Perinatal Depression

AJMC Staff

Half of children in with treatable mental health disorders in the United States do not get treatment; a small study demonstrated benefit with immunotherapy for glioblastoma; a task force recommends counseling services for new mothers at risk of depression.

February 13th 2019

Despite Being Involved in Cancer Treatment Decisions, PCPs Lack Knowledge, Confidence

Jaime Rosenberg

While one-third of primary care providers (PCPs) reported participating in breast cancer treatment decisions with their patients, a significant amount of them also indicated that they were not comfortable or did not feel that they had the necessary knowledge to participate in the treatment decision-making process.

February 13th 2019

Is Immunotherapy the Future of Glioblastoma Treatment?

Samantha DiGrande

Immunotherapy has seen great success in the treatment of numerous cancers, from melanoma to lung, breast, colorectal, kidney, and even some brain cancers. But thus far, despite several attempts, the devastating brain disease glioblastoma has not been among the immunotherapy success stories. In fact, glioblastoma researchers have had few advances in more than a decade.

February 12th 2019

Rutgers' Janice Mehnert, MD, on Biomarkers, Being Inclusive in Clinical Trials, and Taking Time to Weigh the Options

Mary Caffrey

From her vantage point at Rutgers Cancer Institute of New Jersey, Janice Mehnert, MD, has had a front-row seat to the immuno-oncology revolution. Mehnert returned to her alma mater in 2007, and since 2014, she has headed Rutgers’ Phase I/ Developmental Therapeutics Program; she is also head of the melanoma research team. Her work on the KEYNOTE-028 trial has produced important results in multiple cancers, including neuroendocrine tumors, thyroid cancer, small cell lung cancer, and, recently, advanced ovarian cancer.

February 12th 2019

Preparing Patients and the Health System for Curative Therapies in the Pipeline

Laura Joszt, MA

Experts at the “Paying for Cures: Ensuring patient access and system sustainability" event discussed how the healthcare system can pay for curative therapies that have high upfront costs with benefits that accrue over time.

February 12th 2019

Treatment Advances Averted More Than Half a Million Breast Cancer Deaths Over 3 Decades

Wallace Stephens

Preventive screening and treatment advances have contributed to saving lives for patients with breast cancer. A new study has identified that these changes could be responsible for averting up to 614,500 breast cancer deaths since 1989.

February 10th 2019

Identifying Patient Preferences in MM Treatment Improves Shared Decision Making

Laura Joszt, MA

Two studies presented at the 60th American Society of Hematology Annual Meeting and Exposition examined patient preferences in multiple myeloma (MM) treatment and the importance of understanding these preferences when making treatment decisions.

February 10th 2019

Podcast: This Week in Managed Care—State of the Union Health Initiatives and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 9th 2019

Careful Observation of Ovarian Cysts Safe Alternative to Surgery

Samantha DiGrande

Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.

February 8th 2019

This Week in Managed Care: February 8, 2019

This week, the top managed care news included President Trump's State of the Union address highlighting healthcare; HHS Secretary Alex Azar taking on drug rebates; and physicians asking Congress to fully implement the HITECH Act.

February 6th 2019

Trump Highlights New Initiatives for Childhood Cancer, HIV in State of the Union

Laura Joszt, MA

During his second State of the Union address, President Trump highlighted past bipartisan accomplishments, such as legislation to confront the opioid crisis, but also outlined future priorities, such as addressing the cost of healthcare and prescription drugs.

February 6th 2019

What We're Reading: Obesity and Cancer; Second Patient Treated Under Right-to-Try; Brain Aging

AJMC Staff

February 5th 2019

VA Contract Makes Foundation Medicine Oncology Tests Available to Veterans

Laura Joszt, MA

Foundation Medicine announced that it has won a nationwide contract from the Department of Veterans Affairs National Precision Oncology Program. The contract covers all of Foundation Medicine’s tests.

February 5th 2019

Chronic Pain the Top Reason US Patients Seek Medical Marijuana

Allison Inserro

Chronic pain accounted for 62.2% of all patient-reported qualifying conditions under which US patients sought medical marijuana, according to a new paper in Health Affairs.

February 3rd 2019

Podcast: This Week in Managed Care—Congressional Drug Price Hearings and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 2nd 2019

Predicting AML Outcomes by Monitoring Minimal Residual Disease

Laura Joszt, MA

Abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition looked at how monitoring minimal residual disease can help predict outcomes in acute myeloid leukemia (AML).

...

30 31 32 33 34 35 36 37 38

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions